title: Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors.
abstract: Several previous studies have suggested that patients with brain metastases should be treated with individualized approaches taking into account prognostic factors that influence survival. Whether or not radiotherapy represents overtreatment in patients with adverse prognostic features is currently being addressed in the randomized QUARTZ trial (best supportive care (BSC) vs. whole brain radiotherapy (WBRT)). However, inclusion is limited to patients with primary non-small cell lung cancer. Therefore, we analyzed a broader patient population with different primary tumors managed with BSC or WBRT (intended total dose 20 or 30 Gy). Survival was examined by uni- and multivariate analyses including matched pairs. Median overall survival of all 113 patients was 2 months. No significant difference between BSC and 20 Gy WBRT was observed. A slight but significant improvement was observed in the 30 Gy WBRT group (median 2.2 vs. 1.7 months). The magnitude of difference is not clinically meaningful. Subgroup analyses revealed that improved survival after 30 Gy WBRT was limited to patients with primary small cell lung cancer. In conclusion, these results confirm and extent interim results from the QUARTZ trial, suggesting that BSC is a reasonable choice in patients with limited survival expectation. Further efforts are necessary to improve identification of patients who are likely to benefit from WBRT, e.g. by refining available survival prediction tools, and to confirm that management of those with small cell lung cancer should include a less restricted use of WBRT.
authors: Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway, carsten.nieder@nlsh.no.
authors: Carsten
authors: C
authors: Nieder
authors: Jan
authors: J
authors: Norum
authors: Astrid
authors: A
authors: Dalhaug
authors: Gro
authors: G
authors: Aandahl
authors: Adam
authors: A
authors: Pawinski
mesh_terms: D000368:Aged; D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D016371:Cranial Irradiation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies
references: Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803
references: 10098435
references: Clin Exp Metastasis. 2013 Apr;30(4):471-82
references: 23224985
references: Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):510-4
references: 17931798
references: Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
references: 9128946
references: Cancer. 2011 Jun 1;117(11):2505-12
references: 24048799
references: Am J Roentgenol Radium Ther Nucl Med. 1971 Feb;111(2):334-6
references: 5541678
references: Clin Exp Metastasis. 2013 Feb;30(2):201-13
references: 22915160
references: J Clin Oncol. 2004 Apr 1;22(7):1293-300
references: 15051777
references: ScientificWorldJournal. 2012;2012:609323
references: 22593701
references: Oncology. 2010;78(5-6):348-55
references: 20733338
references: Cancer. 2002 Apr 15;94(8):2265-72
references: 12001126
references: J Clin Oncol. 2012 Feb 1;30(4):419-25
references: 22203767
references: Cancer. 1996 Aug 15;78(4):711-6
references: 8756361
references: Clin Exp Metastasis. 2012 Dec;29(8):949-56
references: 22644728
references: Clin Oncol (R Coll Radiol). 2013 Mar;25(3):e23-30
references: 23211715
references: Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61
references: 19942357
references: Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e469-73
references: 21477949